Nuvectis Pharma enters this deal carrying a market cap well under $100 million, yet the license it just signed with Haisco Pharmaceutical gives it ex-China rights to two late-stage compounds that target some of the most commercially competitive ground in rare disease and oncology. That mismatch between company size and asset ambition is the entire strategic bet here.
The more immediately legible asset is NXP100, an oral once-daily Complement Factor B inhibitor for which Haisco already has two Marketing Authorization Applications under review in China. In the treatment-naive PNH study, 59.5% of patients on NXP100 achieved hemoglobin levels at or above 12 g/dL without transfusion, compared with 8.3% on eculizumab, a gap that is hard to dismiss as noise. The same compound is in a Phase 3 trial for IgAN and a Phase 2 for lupus nephritis, which matters because Novartis’ iptacopan (Fabhalta) already holds FDA accelerated approval for IgAN proteinuria reduction, establishing both the regulatory pathway and the commercial proof-of-concept Nuvectis will need to convince investors. The oral, once-daily convenience argument against IV or subcutaneous standards of care is the positioning anchor, and the PNH head-to-head data against eculizumab gives Nuvectis real clinical ammunition rather than inference.
NXP200, the brain-penetrant oral paradox-breaker BRAF inhibitor, is the longer-duration story. It targets both V600 and non-V600 BRAF mutations, a mechanistic scope that older-generation BRAF inhibitors do not cover cleanly, and it has shown single-agent responses across CNS tumors, colorectal cancer, NSCLC, and melanoma in the ongoing Phase 1b. Haisco’s credibility as a partner is not abstract: it has completed licensing deals with Eli Lilly and AbbVie in the second quarter of 2026 alone, and envudeucitinib, a compound Haisco discovered and licensed to Alumis, posted positive Phase 3 results in plaque psoriasis earlier this year. That track record of generating licensable, clinically validated assets reduces some of the diligence risk that typically accompanies small-company in-licensing from Chinese developers.
The single marker worth watching is whether Nuvectis files an IND for NXP100 in PNH before the end of 2026. The Chinese MAA data are robust enough to anchor an ex-China regulatory strategy, and how quickly that filing materializes will tell the market whether Nuvectis has the operational bandwidth to actually run the expansion it just announced.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
